Major manufacturers of vaccines against the new coronavirus report strong revenue growth alongside the spread of more contagious strains
The American pharmaceutical company Pfizer said on Wednesday that it received $ 7.8 billion in sales in the second quarter from its vaccine against Covid-19, which it produces together with the German BioNTech. At the same time, the company raised its forecast for vaccine sales in 2021 to $ 33.5 billion from $ 26 billion. The reason – The delta option is spreading and scientists are discussing whether people will need to speed up vaccination.
The company also said it could apply for an emergency use permit for a potential booster dose as early as August, noting that it is likely to be needed to improve protection against the resurgence of infections in many countries. Reuters.
New data show that a third dose generates virus-neutralizing antibodies more than 5 times higher in younger people and more than 11 times higher in older people than those received from two doses, Pfizer said.
What gains new vaccine
The company’s financial results for the second quarter also exceeded Wall Street’s expectations regarding profits and revenues, announced CNBC. Here’s how Pfizer did against Wall Street expectations, according to Refinitiv averages:
Adjusted earnings per share: $ 1.07 per share against 97 cents per share expected
Revenue: $ 18.98 billion against $ 18.74 billion in forecast
Shares of Pfizer rose 2% to $ 42.98 one in the morning trade.
Pfizer now expects full-year earnings in the range of $ 3.95 to $ 4.05 per share. This is an increase from the previous range of 3.55 – 3.65 dollars per share.
–
The second quarter was remarkable, especially in that the speed and effectiveness of our efforts with BioNTech to support the world’s vaccination against Covid-19 are unprecedented, with more than a billion doses of BNT162b2 now delivered worldwide, the CEO said. of Pfizer Albert Burla.
Last week, Johnson & Johnson forecast to sell $ 2.5 billion worth of vaccines against Covid-19 for $ 2.5 billion all year, while Moderna, Pfizer’s competitor in mRNA vaccines, forecast $ 19.2 billion.
Third dose or a new vaccine
CNBC also highlighted Pfizer’s intention for the third dose, explaining that the reason for this was the observed signs of weakened immunity caused by the Covid vaccine. The company is developing a booster vaccination to target the Delta variant.
“Global demand for the virus vaccine is expected to continue, and the overall positive attitude towards the Pfizer vaccine … puts the company in a strong position to take advantage of the future,” UK.Investing.com analyst Samuel Indic told Reuters.
Pfizer and BioNTech plan to test a version of the vaccine next month specifically designed for the rapidly spreading Delta variant, with the first batch already in production, Pfizer said.
–
